126 results about "Mda mb 231" patented technology

Chemotherapeutic treatment for certain cancers may be combined with low intensity, intermediate frequency alternating electric fields that are tuned to a particular type of target cell. When the tuned fields were combined with Paclitaxel, Doxorubicin or Cyclophosphamide, excellent results were obtained against human breast cancer cells (MDA-MB-231) and non-small cell lung (H1299) carcinomas in culture. More specifically, cell proliferation inhibition similar to that obtained by drug alone was reached by exposure to the combined treatment at drug concentrations between one and two orders of magnitude lower than for drug-only regimens of treatment.

Chemotherapeutic treatment for certain cancers may be combined with low intensity, intermediate frequency alternating electric fields that are tuned to a particular type of target cell. When the tuned fields were combined with Paclitaxel, Doxorubicin or Cyclophosphamide, excellent results were obtained against human breast cancer cells (MDA-MB-231) and non-small cell lung (H1299) carcinomas in culture. More specifically, cell proliferation inhibition similar to that obtained by drug alone was reached by exposure to the combined treatment at drug concentrations between one and two orders of magnitude lower than for drug-only regimens of treatment.

The invention discloses CRISPR-Cas9 targeting knockout of human breast cancer cell RASSF2 gene and specific sgRNA of RASSF2 gene. According to the method, the sgRNA of specific targeting RASSF2 gene is obtained, wherein the base sequence of the sgRNA is represented by SEQ ID NO.1; construction of the sgRNA of RASSF2 gene into a lentiviral vector system is carried out, wherein the lentiviral vectorsystem contains Cas9 protein; and at last, human breast cancer cell MDA-MB-231 is infected with the CRISPR-Cas9 lentivirus containing the sgRNA so as to obtain a cell strain with obviously reduced RASSF2 protein expression level. The operation and the steps are simple; the sgRNA targeting performance is excellent; cutting efficiency on RASSF2 gene is high; the constructed CRISPR-Cas9 lentiviral vector system is high in knockout efficiency, and is capable of realizing specific knockout of RASSF2 gene to obtain human breast cancer cells without RASSF2 gene, so that powerful instrument is provided for study on the action mechanisms of RASSF2 in breast cancer celles.

The invention discloses a CRISPR-Cas9 targeted and knockout human breast cancer cell SLC30A1 gene and the specific sgRNA of the gene. Firstly, sgRNA for specific targeting of the SLC30A1 gene is obtained, and a base sequence of the sgRNA is shown in SEQ ID NO.1; secondly, the sgRNA of the SLC30A1 gene is constructed to a lentivirus vector system containing Cas9 proteins; finally, CRISPR / Cas9 lentivirus containing the sgRNA is infected with a human breast cancer cell MDA-MB-231 to obtain a cell strain of which the SLC30A1 protein expression level is obviously reduced. The CRISPR-Cas9 targeted and knockout human breast cancer cell SLC30A1 gene and the specific sgRNA of the gene disclosed by the invention have the advantages of simple operation steps, good sgRNA targetability and high cuttingefficiency on the SLC30A1 gene; in addition, the constructed CRISPR / Cas9 lentivirus system has the advantage of high knockout efficiency and can specifically knock out the SLC30A1 gene so as to obtain the human breast cancer cell having the SLC30A1 gene knocked out; therefore, a powerful tool is provided for further researching an action mechanism of the SLC30A1 in breast cancer cells.

The invention belongs to the technical field of biomedicine detection, in particular to a method for preparing a nano-fluorescent probe with the quantum dots and an application of the nano-fluorescent probe with the quantum dots on tumor detection. According to the method, aiming at the defects that the traditional preparation method of the quantum dots is complicate to operate and high in cost, a simple and cheap water phase synthetic technique with the quantum dots is provided. The specific synthetic process comprises the synthesis of the water soluble quantum dots, the synthesis of a biocompatible modifier (mPEG) and a tumor cell targeting modifier (cRGD) with the sulfydryl functional groups and a direction reaction between the quantum dots and the two modifiers with the sulfydryl functional groups. According to the method provided by the invention, the preparing raw materials are easy to obtain, the whole preparation process is covalent modification under the conventional condition and the properties of the quantum dots and the modifiers are not changed, and the functions of in vivo long circulation and special cell targeting are simultaneously given for the quantum dots through a one-step reaction, so that the cost is effectively reduced. The modified fluorescent and bright quantum dots obtained by the method are about 5nm in particle size, strong in anti-photo-bleaching property, and have good biocompatibility. The transfection efficiency of the quantum dots on human breast cancer MDA-MB-231 cells can be effectively regulated and controlled by further adjusting the mole ratio of mPEG to cRGD on the surfaces of the quantum dots, so that the nano-fluorescent probe with quantum dots can be applied to the cell fluorescent imaging detection of the tumor targeting.

The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.

The invention relates to the technical field of biological control of breast cancer disease and discloses a polypeptide for promoting apoptosis of breast cancer cells by targeted uptake of siRNA. Thepolypeptide comprises a polypeptide 1; the sequence of the polypeptide 1 is H-Ile-Phe-D-Trp-Leu-Leu-Trp-Gln-Gly-Arg-Gly-Gly-Gly-Arg-Arg-Arg-Arg-Arg-Arg-Arg-OH. A detection method for the polypeptide for promoting the apoptosis of the breast cancer cells by targeted uptake of the siRNA comprises the following steps: firstly, culturing the breast cancer cells: selecting breast cancer cells MDA-MB-231, culturing the breast cancer cells MDA-MB-231 by adopting a DMEM culture medium, and sequentially adding 10 percent of fetal calf serum, 100 unit / ml of penicillin and 100g / mL of streptomycin in theculture medium. According to the polypeptide for promoting the apoptosis of the breast cancer cells by targeted uptake of the siRNA, the polypeptide 1 wraps the siRNA to form nanoparticles for targeting delivery of the siRNA to the breast cancer cells; the nanoparticles can realize the targeting delivery of the siRNA through a surface receptor of the breast cancer cells and have little damage to normal cells, and the practicality of the polypeptide is improved; meanwhile, the targeting delivery of TRPC1 siRNA by using the polypeptide 1 causes the apoptosis of the breast cancer cells, so that the effect of treating breast cancer is realized.

The invention relates to a polypeptide with tumor-targeting performance and a preparation method. The structure of the aminophenol sequence of the polypeptide is CASPSGALRSC or CFPVPGHDLVC or CFSVPGHDIVC or CTPMSLSLSEC or CYTYPLGWHIC. The pC89 phage peptide library expressing protein polypeptides with different sequences of 108 and human breast cancer cell lines MDA-MB-231 are repetitively cocultured for a few times; filtration can penetrate cell membrane to enter into the phages expressing specific polypeptide in cytolymph and / or karyon, and phages are amplified in vitro in order to carry out DNA sequencing and deduce an exogenous amino acid sequence inserted in the phages; the filtered specific polypeptide phages, other human tumor cells and normal cells are cocultured in vitro, and the tumor cell specificity of the polypeptide phages is tested; according to the testing results of polypeptide sequence and cell specificity, the polypeptide with tumor targeting is artifically synthesized. The invention as a specificity carrier of the mammary cancer-targeting genetic therapy has potential clinic application value. The invention also provides a strong technical support for the filtration of affinity specificity polypeptide of other types of malignant tumor cell strains. Moreover, the polypeptide only contains nine to eleven amino acid residues, so the polypeptide can be easily synthesized, the change of spacial position is relatively less, the quality control of the polypeptide is easy, and use is convenient.

The invention belongs to the field of medicinal chemistry, provides novel application of a tyrosine kinase inhibitor DCC-2036, and in particular discloses application of the tyrosine kinase inhibitor DCC-2036 in preparation ofmedicines for preventing or treating triple negative breast cancer. Tests show that the tyrosine kinase inhibitor DCC-2036 is capable of inhibiting proliferation and invasion and metastasis of TNBC(Triple Negative Breast Cancer) cell systems MDA-MB-231 and HS-578T, and moreover the inhibition function of the tyrosine kinase inhibitor DCC-2036 upon cell proliferation is prior to those of most TNBCclinicalfirst-line treatment medicines. Meanwhile, tests further show thatreceptor tyrosine kinaseAXL is a key target of DCC-2036 to take effects into play in TNBC cells, the tyrosine kinase inhibitor DCC-2036 targets AXL and further regulates downstream signal paths to take the anti-tumor function into play in the TNBC and is good in targeted therapy specificity and remarkable in effect, and normal tissue is generally not damaged.

The invention discloses a thiazole bipyrazolone compound as well as applications thereof in preparing a small molecular inhibitor of Bcl-2 family proteins and antitumor drugs, the thiazole bipyrazolone compound has the above structural formula, and the thiazole bipyrazolone compound has the activity for inhibiting the combination of Bcl-xL and natural substrate polypeptide (Bid BH3 polypeptide) in the micromole range, and can serve as the small molecular inhibitor of the Bcl-2 family proteins for inhibiting the anti-apoptosis activity thereof; and the compound shows a certain inhibitory activity to human breast cancer MDA-MB-231 cells and MCF-7 cells, and is expected to be developed into the antitumor drugs of targeted Bcl-2 family proteins.

The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-κB and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL / lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-κB and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL / lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

The invention relates to an application of a flavonoid compound, the flavonoid compound is 3, 3', 4', 5, 7-pentahydroxyflavone dihydrate, the ELISA and protein fluorescence quenching experiments provethat the compound can effectively inhibit interaction of PD-1 / PD-L1 proteins, and has a strong affinity for PD-L1 protein. Cell clone number formation and ELISA detection of IL-2 secretion assay prove that the compound can effectively enhance the tumor killing activity of T lymphocyte Jurkat cells against MDA-MB-231 and NCI-H460 tumor cells as well as the expression level of IL-2, and then reverse T cellular immunosuppression. The research results of the application provide a drug for tumor immunotherapy targeting the PD-1 / PD-L1 immunological test site.

The invention belongs to the technical field of medicine and discloses a preparation method of an oxygen bridge dicycloheptene compound containing a resveratrol group. One of a 3-(4-hydroxyphenyl)-4-(((E)-3, 5-dihydroxystyryl)phenyl)furan compound and a 3, 4-bis(4-hydroxy-phenyl)furan compound and one of a vinylsulfonate and a vinylsulfonate derivative as raw materials undergo a reaction without a catalyst at 90 DEG C for 8h to produce the oxygen bridge dicycloheptene compound containing a resveratrol group. The oxygen bridge dicycloheptene compound has an action method different from that of the existing anti-breast cancer drug tamoxifen. The oxygen bridge dicycloheptene compound can effectively inhibit growth of breast cancer cells MCF-7 and triple-negative breast cancer cells MDA-MB-231, has good anti-inflammatory activity and has an application prospect in breast cancer treatment.

A novel inhibitor of Rac activity based on the structure of the established Rac / Rac-GEF inhibitor NSC23766 is discloses. The compound EHop-016, with an IC50 of 1.1 μM, is a 100-fold more efficient inhibitor of Rac activity than NSC23766. EHop-016 is specific for Rac1 and Rac3 at concentrations ≦5 mM. At higher concentrations, EHop-016 inhibits the close homolog Cdc42. In MDA-MB-435 cells, EHop-016 (≦5 mM) inhibits the association of the Rac-GEF Vav2 with a nucleotide-free Rac1(G15A), which has a high affinity for activated GEFs. EHop-016 does not affect the association of the Rac-GEF Tiam-1 with Rac1(G15A) at similar concentrations. EHop-016 also inhibits the Rac activity of MDA-MB-231 metastatic breast cancer cells and reduces Rac-directed lamellipodia formation in both cell lines. EHop-016 decreases Rac-downstream effects of p21-activated kinase (PAK)1 activity and directed migration of metastatic cancer cells. At low concentrations (<5 μM), EHop-016 does not affect cell viability.

Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU-145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line, MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein. Transfection of DU-145 and PC-3 cells with a full-length human prostasin cDNA restored prostasin expression and reduced the in vitro invasiveness by 68% and 42%, respectively. Transfection of MDA-MB-231 and MDA-MB-435s cells with a full-length human prostasin cDNA restored prostasin expression and reduced the in vitro invasiveness by 50% for either cell line. The prostasin gene promoter region was found to be hypermethylated at specific sites in invasive cancer cells.

Spiro indolone compounds, a preparing method, a medicine composition and uses of the compounds are disclosed. In particular, the invention provide spiro indolone compounds shown as a formula I or II, a preparing method of the spiro indolone compounds and uses of the compounds in preparation of antitumor medicines. The compounds have a spiro indolinone skeleton, and the preparing method and potential uses of the compounds have not been reported before. The compounds have obvious killing functions for human cancer cells, particularly a human breast cancer cell strain MDA-MB-231, a human cervical cancer cell strain HeLa or a human lung cancer cell strain A549, have high selectivity, have potentials as novel antitumor medicines and have a good market prospect.

The invention discloses application of a mauremys mutica polypeptide mixture in the field of antitumor drug preparation and further discloses an antitumor drug which contains the mauremys mutica polypeptide mixture. The mauremys mutica polypeptide mixture has an excellent antitumor effect, and according to experimental verification, the mauremys mutica polypeptide mixture is capable of evidently inhibiting proliferation of breast cancer cells MDA-MB-231 and MCF-7, retarding a G2-M period of MDA-MB-231 and an S period of MCF-7 and evidently inhibiting proliferation of breast cancer cells MCF-7 in BALB / c-Nude mice bodies. Therefore, the mauremys mutica polypeptide mixture has a promising application prospect in the field of antitumor drug preparation.

The invention relates to a triple negative breast cancer marker COL4A2 and application thereof. By means of comparison researches on different cell lines, a specifically expressed gene COL4A2 is discovered in the triple negative breast cancer cell line MDA-MB-231, the sequence interfering with expression of the COL4A2 gene is further designed and synthesized and is respectively constructed to plasmid vectors to transfect the cell MDA-MB-231, and a sequence capable of efficiently interfering with expression of the COL4A2 gene is successfully obtained. The triple negative breast cancer marker COL4A2 and the siRNA efficiently interfering with the marker gene have an important clinical application value.

The invention provides a furanocoumarin-Base derivative, wherein the structural formula of the derivative is as shown in the following formula 6 or 7; the derivative is synthesized by performing ringformation and coupling reaction on parabromoaniline,paraformaldehyde, 4-hydroxycoumarin, isonitrile and n-butyllithium; and the synthesis process is mild in reaction condition, short in reaction timeand high in yield. The Base derivative containing a coumarin fragment has excellent luminescent property and high bioactivity; some of the products have anti-tumor activity, show high-selectivity inhibition on human triple negative breast cancer cells (MDA-MB-231) and have research value of being further developed into anti-tumor medicines; and the other products can be applied to synchronous detection on neuroblastoma metabolites homovanillic acid (HVA) and vanilmandelic acid (VMA) and have the potential of being developed into a high-efficiency fluorescent probe for human neuroblastoma earlywarning and definite diagnosis.

The invention discloses a refined polyphenol which is prepared from Trapa acornis Nakano shells and has a tumor suppression function as well as a preparation method and an application of the polyphenol. The method comprises steps as follows: 1) the Trapa acornis Nakano shells are dried in the shade, crushed and sieved; 2) a crude extract is prepared; 3) the refined polyphenol is prepared. The refined polyphenol has a very good inhibition effect on A549, MDA-MB-231, MCF-7 and LOVO tumor cells in in-vitro cell experiments. The waste Trapa acornis Nakano shells are used as a raw material, active components are prepared with a modern extraction and separation means and pharmacological activity screening combined method, waste is turned into wealth, and an anti-tumor drug is expected to be developed.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition capable of inhibiting tumor metastasis. Active ingredients of the traditional Chinese medicine composition include, by weight, 20-50 parts of radix astragali, 10-20 parts of rhizoma curcumae, 20-40 parts of radix pseudostellariae, 10-20 parts of poriacocos, 20-40 parts of rhizoma atractylodis macrocephalae, 20-40 parts of coix seed, 10-20 parts of fructus ligustri lucidi, 10-20 parts of fructus lycii, 10-20 parts of herba cistanche, 10-20 parts of fructus corni, 10-20 parts of radix polygonum multiflorum preparata, 15-30 parts of hedyotis diffusa and 15-30 parts of herba scutellariae barbatae. The invention further provides a preparation method and application of the traditional Chinese medicine composition. Main treatment rules of the composition are to tonify spleen and kidney, the composition can remarkably inhibit breast cancer cell MDA-MB-231 scratch formation, can inhibit cell migration and intrusion and has remarkable anti-metastasis effect; cytological experiments prove that the composition has efficacy of inhibiting tumor metastasis, and clinical experiments prove that the composition has remarkable effect on improving life quality of tumor patients.

The invention relates to a single-chain antibody capable of specific binding and capable of activating human death receptor 5 (DR5), and belongs to a full-humanized antibody; the single-chain antibody is obtained by performing quintuple screening in a high-capacity full-humanized phage antibody library by using human death receptor DR5 extracellular protein as a target antigen; the single-chain antibody may be acquired by induced expression in Escherichia coli, nickel ion affinity chromatography and molecular-exclusion chromatographic purification; pharmacodynamic experiments prove that the single-chain antibody is efficient in suppressing the growth of DR5 positive colon cancer cell COLO205 and breast cancer cell MDA-MB-231; the single-chain antibody and other antibodies modified therefrom, including full-length, bispecific or fusion protein forms, may act as drugs for positive tumor targeting therapy of death receptor DR5; the single-chain antibody has the advantages such as low immunogenicity, high specificity and high penetrability and is an ideal targeting tumor therapeutic drug.

The invention discloses acylation flavone glycoside named camellikaempferoside A and a preparing method and application thereof. At first, the structure of camellikaempferoside A is provided, and then a method for separating camellikaempferoside A from Fuzhuan tea to prepare and obtain camellikaempferoside A is provided; when a monomeric compound is prepared, at first, Fuzhuan tea is taken and smashed; then organic solvent is used for extracting the smashed Fuzhuan tea, and an extracting solution is concentrated in a pressure reducing mode to prepare paste extract; the paste extract is separated and purified to obtain camellikaempferoside A. The invention further provides application of acylation flavone glycoside named camellikaempferoside A to preparation of medicine for resisting breast cancer (MCF-7 and MDA-MB-231). The acylation flavone glycoside with bioactivity has great significance in the agriculture and medicine field, and provides a wide prospect for effectively developing and utilizing the Fuzhuan tea; the preparing method is simple and low in cost.

The invention discloses camphoryl pyrimidines, and a preparation method and an anti-tumor activity study thereof. With camphor as a raw material and under an alkaline catalysis condition, a series ofalpha,beta-unsaturated ketones are obtained through aldol condensation reaction of camphor with different aromatic aldehydes respectively, a series of camphoryl pyrimidines are obtained through annulation reaction of alpha,beta-unsaturated ketones with guanidine hydrochloride through catalysis of potassium tert-butoxide, and the anti-tumor activity of the synthesized camphoryl pyrimidines is studied. Experiments show that the camphoryl pyrimidines have good inhibitory activity on human multiple myeloma cells (RPMI-8226), human breast cancer cells (MDA-MB-231) and human non-small cell lung cancer cells (A549), have less toxicity on normal cell human gastric mucosa cells (GES-1), and have potential anti-tumor application value.

The invention belongs to the field of radiation sensitizing agents, in particular to an application of BTG2 (B cell translocation gene 2) in preparing a tumor radiation sensitizing agent for ionizing radiation including X-rays. The invention discloses an application of liposome mediated eukaryotic expression plasmid pcDNA3-BTG2 in preparing the radiation sensitizing agent, wherein the liposome mediated eukaryotic expression plasmid pcDNA3-BTG2 is transfected to MCF-7 (macrophage chemotactic factor-7) breast cancer cells and MDA-MB-231 breast cancer cells and expressed successfully, and the BTG2 protein can up-regulate the proapoptosis Bax protein and down-regulate the cell cycle regulatory protein Cyclin D1, and by promoting the cell apoptosis, G0 / G1 phase arrest of the cells is promoted, thereby increasing the sensitivity of the breast cancer cells to ionizing radiation including the X-rays.

The invention relates to a tumor targeting polypeptide and a preparation method thereof. The amino acid sequential structure of the polypeptide of the invention is CFPVPGHDLVC. The preparation method comprises the following steps: co-culturing a pC89 phage peptide library for expressing 108 protein polypeptides with different sequences and human breast cancer cell strain MDA-MB-231 repeatedly for many times; screening phages which express specific polypeptides and can penetrate a cell membrane and enter cytoplasm and / or nucleus, amplifying the phages in vitro and carrying out DNA sequencing, and deducing exogenous amino acid sequences inserted on the phages; co-culturing the screened specific polypeptide phages, other human tumor cells and normal cells in vitro, and detecting the specificity of cell tumor of the polypeptide phages; and according to the polypeptide sequences and the detecting result of the cell specificity, artificially synthesizing the tumor targeting polypeptide. The invention has potential clinical application values for specific vectors of breast cancer targeting gene therapy, and also provides powerful technical support for screening polypeptides with affinity and specificity of other types of malignant tumor cell strains in the future. In addition, the polypeptide of the invention contains only 9-11 amino acid residues, can be synthesized easily, and has relatively small spatial position change, easy quality control of the polypeptide and convenient use.

A novel inhibitor of Rac activity based on the structure of the established Rac / Rac-GEF inhibitor NSC23766 is discloses. The compound EHop-016, with an IC50 of 1.1 μM, is a 100-fold more efficient inhibitor of Rac activity than NSC23766. EHop-016 is specific for Rac1 and Rac3 at concentrations ≦5 mM. At higher concentrations, EHop-016 inhibits the close homolog Cdc42. In MDA-MB-435 cells, EHop-016 (≦5 mM) inhibits the association of the Rac-GEF Vav2 with a nucleotide-free Rac1(G15A), which has a high affinity for activated GEFs. EHop-016 does not affect the association of the Rac-GEF Tiam-1 with Rac1(G15A) at similar concentrations. EHop-016 also inhibits the Rac activity of MDA-MB-231 metastatic breast cancer cells and reduces Rac-directed lamellipodia formation in both cell lines. EHop-016 decreases Rac-downstream effects of p21-activated kinase (PAK)1 activity and directed migration of metastatic cancer cells. At low concentrations (<5 μM), EHop-016 does not affect cell viability.

The invention discloses a novel terpene compound with an aldehyde group and a preparation method and application thereof. The structure of the novel terpene compound with the aldehyde group is shown as a formula (I). The method for preparing the novel terpene compound with the aldehyde group comprises the following steps that 1, dry fruit of monkey bread is taken as a raw material, and an extract-shaped ethanol extract is obtained through ethanol extraction and concentration; 2, the extract-shaped ethanol extract is mixed and suspended in water and then extracted by ethyl acetate, and an organic phase is obtained; 3, The organic phase is separated through middle-low-pressure preparative chromatography, and gradient elution is performed with methanol-water containing 10%-100% of methanol by volume content, wherein the eluted portion of 100% methanol is eluted by acetonitrile-water with the volume ratio of 10:90-50:50 through semi-preparative efficient liquid-phase chromatographic separation, and then the novel terpene compound which has the aldehyde group and is shown in the formula (I) is obtained. The invention further provides the application of the compound (I) in preparation of antineoplastic drugs especially for human breast cancer MDA-MB-231 cells, and the certain inhibiting action is shown.

The invention relates to genomics, molecular biology, cell biology, gene engineering and clinical medicine, in particular to application of a human ING4 and IL-24 double-gene coexpression vector as a radiotherapy sensitizing agent. Before the radiotherapy, the human ING4 and IL-24 double-gene coexpression vector is led in tumor cells so that the human ING4 and IL-24 genes are expressed in the tumor cells, and then the radiotherapy is carried out. The Ad-ING4-polyA<delta 296-298>+CMV-IL-24 can retard lots of tumor cells in the proliferative stage in the G2 / M stage and is beneficial to enhancing the irradiation sensitivity. The MTT and the FCM detection results further show that the Ad-ING4-IL-24 combined radiotherapy has the effect of obviously inhibiting the growth of the SPC-A1 lung adenocarcinoma cells, MDA-MB-231 breast carcinoma cells and the transplanted tumor thereof and inducing the cell apoptosis, exceeds the Ad-ING4-IL-24 single genome and the radiotherapy single genome, and presents obvious radiotherapy sensitization synergistic effect. Therefore, the human ING4 and IL-24 double-gene coexpression vector can be used for enhancing the sensitivity of the tumor cells to the radiotherapy.